Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe DiseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup that damages muscles and can affect breathing and, in some cases, the heart.
Cambridge, Mass. – November 4, 2016 – Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the first patient has been enrolled and received an infusionA method of delivering medication through an IV. in a pivotal Phase 3 clinical trialA research study that tests new treatments or approaches in people. named COMET for the investigational therapy neoGAA. NeoGAA is a second- generation enzymeA protein that helps the body carry out chemical reactions. replacement therapy being studied for the treatment of Pompe disease.
